SAFETY AND EFFICACY OF ABT-494, A NOVEL SELECTIVE JAK1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

被引：1

作者：

Genovese, M. C. ^{[1
]}

Smolen, J. S. ^{[2
,3
]}

Weinblatt, M. E. ^{[4
]}

Meerwein, S. ^{[5
]}

Camp, H. S. ^{[5
]}

Wang, L. ^{[5
]}

Othman, A. A. ^{[5
]}

Khan, N. ^{[5
]}

Jungerwirth, S. ^{[5
]}

机构：

[1] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA

[2] Med Univ Vienna, Vienna, Austria

[3] Hietzing Hosp, Vienna, Austria

[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[5] AbbVie Inc, N Chicago, IL USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷

关键词：

D O I：

10.1136/annrheumdis-2016-eular.3698

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0223

引用

页码：141 / 142

页数：2

共 50 条

[1] Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Genovese, Mark C.
Smolen, Josef S.
Weinblatt, Michael E.
Burmester, Gerd R.
Meerwein, Sebastian
Camp, Heidi S.
Wang, Li
Othman, Ahmed A.
Khan, Nasser
Pangan, Aileen L.
Jungerwirth, Steven
ARTHRITIS & RHEUMATOLOGY, 2016, 68 (12) : 2857 - 2866
[2] SAFETY AND EFFICACY OF ABT-494, A NOVEL SELECTIVE JAK1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO ANTI-TNF BIOLOGIC THERAPY
Kremer, J. M.
Keystone, E. C.
Emery, P.
Camp, H. S.
Friedman, A.
Wang, L.
Othman, A. A.
Khan, N.
Jungerwirth, S.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1038 - 1039
[3] Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Kremer, Joel M.
Keystone, Edward C.
Emery, Paul
Camp, Heidi S.
Friedman, Alan
Wang, Li
Othman, Ahmed A.
Khan, Nasser
Jungerwirth, Steven
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[4] PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE SELECTIVE JAK1 INHIBITOR, ABT-494, IN HEALTHY VOLUNTEERS AND SUBJECTS WITH RHEUMATOID ARTHRITIS
Mohamed, M. -E.
Camp, H.
Jiang, P.
Padley, R.
Asatryan, A.
Othman, A. A.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 258 - 258
[5] Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
Mohamed, Mohamed-Eslam F.
Camp, Heidi S.
Jiang, Ping
Padley, Robert J.
Asatryan, Armen
Othman, Ahmed A.
CLINICAL PHARMACOKINETICS, 2016, 55 (12) : 1547 - 1558
[6] Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
Mohamed-Eslam F. Mohamed
Heidi S. Camp
Ping Jiang
Robert J. Padley
Armen Asatryan
Ahmed A. Othman
Clinical Pharmacokinetics, 2016, 55 : 1547 - 1558
[7] Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor.
Graff, Candace
Schwartz, Annette
Voss, Jeffrey
Wishart, Neil
Olson, Lisa
George, Jonathon
Hyland, Deborah
Camp, Heidi
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S659 - S660
[8] A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
Kremer, Joel M.
Emery, Paul
Camp, Heidi S.
Friedman, Alan
Wang, Li
Othman, Ahmed A.
Khan, Nasser
Pangan, Aileen L.
Jungerwirth, Steven
Keystone, Edward C.
ARTHRITIS & RHEUMATOLOGY, 2016, 68 (12) : 2867 - 2877
[9] SAFETY AND EFFICACY OF ABT-494 (UPADACITINIB), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM CELEST
Sandborn, William J.
Feagan, Brian G.
Panes, Julian
D'Haens, Geert R.
Colombel, Jean Frederic
Zhou, Qian
Huang, Bidan
Enejosa, Jeffrey V.
Pangan, Aileen L.
Lacerda, Ana P.
GASTROENTEROLOGY, 2017, 152 (05) : S1308 - S1309
[10] Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
Genovese, Mark C.
Kremer, Joel
Zhong, Sheng
Friedman, Alan
ARTHRITIS & RHEUMATOLOGY, 2017, 69

← 1 2 3 4 5 →